Swedish firm readies image-guided radiotherapy device
This article was originally published in Clinica
Executive Summary
Elekta predicts that its latest device for simultaneously imaging and treating cancer will be on the market worldwide in 18 month's time and has begun selling an up-gradable platform in preparation. The Swedish company is currently finalising development and testing of the imaging system, which can treat cancers anywhere in the boy, in four hospitals in Europe and North America.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.